Noncoding RNAs in vascular disease

Current Opinion in Cardiology

Volumn 29, Issue 3, 2014, Pages 199-206

  Leung, Amy ^a   Natarajan, Rama ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

lncRNAs; miRNAs; vascular disease

Indexed keywords

ANGIOTENSIN II; ANRIL LONG NON CODING RNA; BIOLOGICAL MARKER; BMI1 PROTEIN; BRAVEHEART LONG NON CODING RNA; CIS ACTING ELEMENT; ESTROGEN RECEPTOR ALPHA; FENDRR RNA; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN; HISTONE DEACETYLASE 3; LONG UNTRANSLATED RNA; MESSENGER RNA; MICRORNA; MICRORNA 126; MICRORNA 143; MICRORNA 145; MICRORNA 17; MICRORNA 221; MICRORNA 222; POLYCOMB REPRESSIVE COMPLEX 2; PROTEIN P53; RECEPTOR INTERACTING PROTEIN 140; RNA BINDING PROTEIN; STAUFEN1 PROTEIN; TERMINAL DIFFERENTIATION INDUCED NON CODING RNA; TRANS ACTING FACTOR; UNCLASSIFIED DRUG;

ACUTE HEART INFARCTION; ATHEROSCLEROSIS; CELL COMMUNICATION; CELL CYCLE PROGRESSION; CELL GROWTH; CELL MIGRATION; CELL NUCLEUS; CHROMATIN IMMUNOPRECIPITATION; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; CYTOPLASM; DOWN REGULATION; ENDOTHELIUM CELL; ENHANCER REGION; GENE EXPRESSION REGULATION; HEART FAILURE; HUMAN; ISCHEMIC HEART DISEASE; MACROPHAGE; MESANGIUM CELL; MESODERM; NONHUMAN; NUCLEOTIDE MOTIF; PRIORITY JOURNAL; PROMOTER REGION; REVIEW; RNA SEQUENCE; SMOOTH MUSCLE FIBER; VASCULAR DISEASE; VASCULAR SMOOTH MUSCLE; X CHROMOSOME INACTIVATION; CARDIOVASCULAR DISEASE; CELLULAR, SUBCELLULAR AND MOLECULAR BIOLOGICAL PHENOMENA AND FUNCTIONS; GENE EXPRESSION; GENETICS; HEART MUSCLE CELL; PHYSIOLOGY; RNA PROCESSING;

ANGIOTENSIN II; CARDIOVASCULAR DISEASES; CELL PHYSIOLOGICAL PROCESSES; GENE EXPRESSION; HUMANS; MYOCYTES, CARDIAC; RNA PROCESSING, POST-TRANSCRIPTIONAL; RNA, LONG NONCODING;

EID: 84899490778     PISSN: 02684705     EISSN: 15317080     Source Type: Journal    
DOI: 10.1097/HCO.0000000000000054     Document Type: Review

References (50)

1. Crick FH. On protein synthesis. Symp Soc Exp Biol 1958; 12:138-163.
2. Guttman M, Amit I, Garber M, et al. Chromatin signature reveals over a thousand highly conserved large noncoding RNAs in mammals. Nature 2009; 458:223-227.
3. Cabili MN, Trapnell C, Goff L, et al. Integrative annotation of human large intergenic noncoding RNAs reveals global properties and specific subclasses. Genes Dev 2011; 25:1915-1927.
4. Guttman M, Garber M, Levin JZ, et al. Ab initio reconstruction of cell typespecific transcriptomes in mouse reveals the conserved multiexonic structure of lincRNAs. Nat Biotechnol 2010; 28:503-510.
5. Khalil AM, Guttman M, Huarte M, et al. Many human large intergenic noncoding RNAs associate with chromatin-modifying complexes and affect gene expression. Proc Natl Acad Sci USA 2009; 106:11667-11672.
6. Consortium EP, Dunham I, Kundaje A, et al. An integrated encyclopedia of DNA elements in the human genome. Nature 2012; 489:57-74.
7. Wang KC, Chang HY. Molecular mechanisms of long noncoding RNAs. Mol Cell 2011; 43:904-914.
8. Mercer TR, Mattick JS. Structure and function of long noncoding RNAs in epigenetic regulation. Nat Struct Mol Biol 2013; 20:300-307.
9. Penny GD, Kay GF, Sheardown SA, et al. Requirement for Xist in X chromosome inactivation. Nature 1996; 379:131-137.
10. Froberg JE, Yang L, Lee JT. Guided by RNAs: X-inactivation as a model for lncRNA function. J Mol Biol 2013; 425:3698-3706.
11. Zhao J, Sun BK, Erwin JA, et al. Polycomb proteins targeted by a short repeat RNA to the mouse X chromosome. Science 2008; 322:750-756.
12. Ohhata T, Hoki Y, Sasaki H, Sado T. Crucial role of antisense transcription across the Xist promoter in Tsix-mediated Xist chromatin modification. Development 2008; 135:227-235.
13. Orom UA, Derrien T, Beringer M, et al. Long noncoding RNAs with enhancerlike function in human cells. Cell 2010; 143:46-58.
14. Melo CA, Drost J, Wijchers PJ, et al. eRNAs are required for p53-dependent enhancer activity and gene transcription. Mol Cell 2013; 49:524-535.
15. Li W, Notani D, Ma Q, et al. Functional roles of enhancer RNAs for oestrogendependent transcriptional activation. Nature 2013; 498:516-520.
16. Lam MT, Cho H, Lesch HP, et al. Rev-Erbs repress macrophage gene expression by inhibiting enhancer-directed transcription. Nature 2013; 498:511-515.
17. Tsai MC, Manor O, Wan Y, et al. Long noncoding RNA as modular scaffold of histone modification complexes. Science 2010; 329:689-693.
18. Huarte M, Guttman M, Feldser D, et al. A large intergenic noncoding RNA induced by p53 mediates global gene repression in the p53 response. Cell 2010; 142:409-419.
19. Cesana M, Cacchiarelli D, Legnini I, et al. A long noncoding RNA controls muscle differentiation by functioning as a competing endogenous RNA. Cell 2011; 147:358-369.
20. Kretz M, Siprashvili Z, Chu C, et al. Control of somatic tissue differentiation by the long noncoding RNA TINCR. Nature 2013; 493:231-235.
21. Hata A. Functions of microRNAs in cardiovascular biology and disease. Annu Rev Physiol 2013; 75:69-93.
22. Chen X, Liang H, Zhang J, et al. MicroRNAs are ligands of Toll-like receptors. RNA 2013; 19:737-739.
23. Hergenreider E, Heydt S, Treguer K, et al. Atheroprotective communication between endothelial cells and smooth muscle cells through miRNAs. Nat Cell Biol 2012; 14:249-256.
24. Creemers EE, Tijsen AJ, Pinto YM. Circulating microRNAs: novel biomarkers and extracellular communicators in cardiovascular disease? Circ Res 2012; 110:483-495.
25. Wang GK, Zhu JQ, Zhang JT, et al. Circulating microRNA: a novel potential biomarker for early diagnosis of acute myocardial infarction in humans. Eur Heart J 2010; 31:659-666.
26. D'Alessandra Y, Pompilio G, Capogrossi MC. MicroRNAs and myocardial infarction. Curr Opin Cardiol 2012; 27:228-235.
27. Tijsen AJ, Creemers EE, Moerland PD, et al. MiR423-5p as a circulating biomarker for heart failure. Circ Res 2010; 106:1035-1039.
28. Fichtlscherer S, De Rosa S, Fox H, et al. Circulating microRNAs in patients with coronary artery disease. Circ Res 2010; 107:677-684.
29. Matsumoto S, Sakata Y, Suna S, et al. Circulating p53-responsive microRNAs are predictive indicators of heart failure after acute myocardial infarction. Circ Res 2013; 113:322-326.
30. Ellis KL, Cameron VA, Troughton RW, et al. Circulating microRNAs as candidate markers to distinguish heart failure in breathless patients. Eur J Heart Fail 2013; 15:1138-1147.
31. Klattenhoff CA, Scheuermann JC, Surface LE, et al. Braveheart, a long noncoding RNA required for cardiovascular lineage commitment. Cell 2013; 152:570-583.
32. Grote P, Wittler L, Hendrix D, et al. The tissue-specific lncRNA Fendrr is an essential regulator of heart and body wall development in the mouse. Dev Cell 2013; 24:206-214.
33. Pasmant E, Sabbagh A, Vidaud M, Bieche I. ANRIL, a long, noncoding RNA, is an unexpected major hotspot in GWAS. FASEB J 2011; 25:444-448.
34. Congrains A, Kamide K, Oguro R, et al. Genetic variants at the 9p21 locus contribute to atherosclerosis through modulation of ANRIL and CDKN2A/B. Atherosclerosis 2012; 220:449-455.
35. Kotake Y, Nakagawa T, Kitagawa K, et al. Long noncoding RNA ANRIL is required for the PRC2 recruitment to and silencing of p15(INK4B) tumor suppressor gene. Oncogene 2011; 30:1956-1962.
36. Yap KL, Li S, Munoz-Cabello AM, et al. Molecular interplay of the noncoding RNA ANRIL and methylated histone H3 lysine 27 by polycomb CBX7 in transcriptional silencing of INK4a. Mol Cell 2010; 38:662-674.
37. Burd CE, Jeck WR, Liu Y, et al. Expression of linear and novel circular forms of an INK4/ARF-associated noncoding RNA correlates with atherosclerosis risk. PLoS Genet 2010; 6:e1001233.
38. Pasmant E, Laurendeau I, Heron D, et al. Characterization of a germline deletion, including the entire INK4/ARF locus, in a melanoma-neural system tumor family: identification of ANRIL, an antisense noncoding RNA whose expression coclusters with ARF. Cancer Res 2007; 67:3963-3969.
39. Folkersen L, Kyriakou T, Goel A, et al. Relationship between CAD risk genotype in the chromosome 9p21 locus and gene expression. Identification of eight new ANRIL splice variants. PLoS One 2009; 4:e7677.
40. Hansen TB, Wiklund ED, Bramsen JB, et al. miRNA-dependent gene silencing involving Ago2-mediated cleavage of a circular antisense RNA. EMBO J 2011; 30:4414-4422.
41. Memczak S, Jens M, Elefsinioti A, et al. Circular RNAs are a large class of animal RNAs with regulatory potency. Nature 2013; 495:333-338.
42. Leung A, Trac C, Jin W, et al. Novel long noncoding RNAs are regulated by angiotensin II in vascular smooth muscle cells. Circ Res 2013; 113:266-278.
43. Alvarez ML, Distefano JK. The role of noncoding RNAs in diabetic nephropathy: potential applications as biomarkers for disease development and progression. Diabetes Res Clin Pract 2013; 99:1-11.
44. Gurha P, Marian AJ. Noncoding RNAs in cardiovascular biology and disease. Circ Res 2013; 113:e115-e120.
45. Hansen TB, Jensen TI, Clausen BH, et al. Natural RNA circles function as efficient microRNA sponges. Nature 2013; 495:384-388.
46. Salzman J, Gawad C, Wang PL, et al. Circular RNAs are the predominant transcript isoform from hundreds of human genes in diverse cell types. PLoS One 2012; 7:e30733.
47. Manolio TA, Collins FS, Cox NJ, et al. Finding the missing heritability of complex diseases. Nature 2009; 461:747-753.
48. Van Aelst LN, Heymans S. MicroRNAs as biomarkers for ischemic heart disease. J Cardiovasc Transl Res 2013; 6:458-470.
49. Tijsen AJ, Pinto YM, Creemers EE. Circulating microRNAs as diagnostic biomarkers for cardiovascular diseases. Am J Physiol Heart Circ Physiol 2012; 303:H1085-H1095.
50. Sheridan C. RaNA therapeutics. Nat Biotechnol 2012; 30:909.